{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-023189","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.396504+00:00","generated_at":"2026-06-05T07:51:17.052031+00:00","sec_items":["1.01","1.02","2.02","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Achieve Life Sciences raises up to $124.2M in registered direct offering and private placement","bullets":["$60M upfront from 13.09M shares at $4.585; warrants could add $64.2M at $4.906 exercise price.","Preliminary cash, cash equivalents and restricted cash of $15.6M as of Dec 31, 2023.","Net proceeds to fund cytisinicline clinical development through NDA submission expected 1H 2025.","Warrants exercisable for 3.5 years or expire 30 days after FDA Day 74 letter acceptance; 4.99% ownership cap.","Concurrent termination of at-the-market sales agreement with Virtu Americas LLC."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-023189","json":"https://secwatch.observer/filing/0000950170-24-023189.json","markdown":"https://secwatch.observer/filing/0000950170-24-023189.md","text":"https://secwatch.observer/filing/0000950170-24-023189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000095017024023189/0000950170-24-023189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000095017024023189/achv-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:51:17.052031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e472200d8c279969f2feccacbdde678888fbda1a","claim":"ACHIEVE LIFE SCIENCES, INC. terminated At-the-Market Sales Agreement with Virtu Americas LLC valued at Termination of at-the-market offering program (effective 2024-02-28).","evidence_excerpt":"Item 1.02 Termination of Material Definitive Agreement As previously disclosed, on December 21, 2021, the Company entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with Virtu Americas LLC (“Virtu”) with respect to an “at-the-market” offering program under which the Company could offer and sell, from time to time at the Company’s sole discretion, shares of Common Stock through Virtu as its sales agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000095017024023189/0000950170-24-023189-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Virtu Americas LLC"},{"label":"Value","value":"Termination of at-the-market offering program"},{"label":"Effective","value":"2024-02-28"}],"fact_type":"material_agreement"},{"claim_id":"fa99f27b1ab44db2a39e94bf9bccde7ff4709bfb","claim":"ACHIEVE LIFE SCIENCES, INC. entered into Securities Purchase Agreement with Purchasers valued at up to 13,086,151 shares at $4.585 per share and warrants (effective 2024-02-28).","evidence_excerpt":"On February 28, 2024, Achieve Life Sciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain purchasers (the “Purchasers”) for the sale of up to 13,086,151 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $4.585 per Share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000095017024023189/0000950170-24-023189-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Purchasers"},{"label":"Value","value":"up to 13,086,151 shares at $4.585 per share and warrants"},{"label":"Effective","value":"2024-02-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}